Back to Results
First PageMeta Content
Pharmacology / Pfizer / GlaxoSmithKline / European Federation of Pharmaceutical Industries and Associations / Division of Signal Transduction Therapy / Pharmaceutical sciences / Boehringer Ingelheim / Pharmaceutical industry


Microsoft Word - CQDM Press Release final English
Add to Reading List

Document Date: 2014-04-08 14:49:59

Open Document

File Size: 53,54 KB

Share Result on Facebook

City

Laval / Ingelheim / /

Company

AstraZeneca Canada / Merck / GlaxoSmithKline Inc. / Business-Led Networks / Boehringer Ingelheim (Canada) Ltd. / Pfizer Canada / /

Country

Germany / Canada / /

Currency

USD / /

/

Event

Business Partnership / /

IndustryTerm

transformative enabling technologies / pharmaceutical industry / biotechnology industries / research-based pharmaceutical / healthcare solutions / manufacturing / pharmaceutical / biopharmaceutical research / /

MedicalCondition

diseases / infectious diseases / /

Organization

CQDM Explore Advisory Committee / CQDM Strategic Orientation Committee / /

Person

Tjark Reblin / Julie Edwards / Bernard Prigent / /

/

Position

Chairman / Vice-President / Research and Business Development / Diane Gosselin Vice-President / Research and Business Development / Manager / Scientific Affairs / Chair / Vice-President and Medical Director / Vice President / Medical and Chief Medical Officer / /

ProvinceOrState

Quebec / /

PublishedMedium

la Recherche / /

Technology

transformative enabling technologies / Drug Discovery / biotechnology / /

URL

www.boehringer-ingelheim.com / www.cqdm.org / www.gsk.ca / /

SocialTag